One in four biologicals subject to safety actions postapproval

By  

Inpharma, Vol. 1, Iss. 1662, 2008-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Rosuvastatin safety: lessons from the FDA review and post-approval surveillance

By Davidson Michael H  

Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. : 547-557

Informa Healthcare

Access to resources Recommend Favorite

Immunisation Safety: A Priority of the World Health Organization's Department of Vaccines and Biologicals

By Duclos P.   Hofmann C-A.  

Drug Safety, Vol. 24, Iss. 15, 2001-01 ,pp. : 1105-1112

Adis International

Access to resources Recommend Favorite

Is the Large Simple Trial Design Used for Comparative, Post-Approval Safety Research?: A Review of a Clinical Trials Registry and the Published Literature

By Reynolds Robert F.   Lem Joanna A.  

Drug Safety, Vol. 34, Iss. 10, 2011-10 ,pp. : 799-820

Adis International

Access to resources Recommend Favorite

Mapping the Safety Profile of Biologicals: A Disproportionality Analysis Using the WHO Adverse Drug Reaction Database, VigiBase

By Giezen Thijs J.   Mantel-Teeuwisse Aukje K.   Meyboom Ronald H.B.   Straus Sabine M.J.M.   Leufkens Hubert G.M.   Egberts Toine C.G.  

Drug Safety, Vol. 33, Iss. 10, 2010-10 ,pp. : 865-878

Adis International

Access to resources Recommend Favorite